Problems of Endocrinology

ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

eng | рус

Preview

Problems of Endocrinology

Advanced search

Archives

Efficacy of standard methods in the treatment of prolactin-secreting pituitary carcinoma

L. I. Astafyeva, P. L. Kalinin, Y. Y. Trunin, G. L. Kobyakov, Y. G. Sidneva

https://doi.org/10.14341/probl13401

Full Text:

PDF (Rus) | HTML (Rus) | XML (Rus) |

Generate QR code

Abstract

Pituitary carcinoma (metastatic neuroendocrine tumor of the pituitary gland) is the pituitary tumor with confirmed craniospinal and/or systemic metastases. These tumors are extremely rare accounting for only 0.1% to 0.5% of all pituitary tumours and are characterized by high mortality. In the presented case, pituitary carcinoma with intracranial metastasis was diagnosed in a young patient 25 years after manifestation of an aggressive recurrent prolactin-secreting pituitary tumor. Standard therapy (removal of metastasis, radiation therapy, cabergoline therapy) resulted in a long-term remission of the disease.

Keywords

aggressive pituitary tumors, pituitary carcinoma, metastases, pituitary neuroendocrine tumor, cabergoline, temozolomide

About the Authors

L. I. Astafyeva

Burdenko Neurosurgery Center
Russian Federation

Ludmila I. Astafyeva - MD, PhD.

16, 4th Tverskaya-Yamskaya street, Moscow 125047

Competing Interests:

none

P. L. Kalinin

Burdenko Neurosurgery Center
Russian Federation

Pavel L. Kalinin - MD, PhD.

Moscow

Competing Interests:

none

Y. Y. Trunin

Burdenko Neurosurgery Center
Russian Federation

Yury Y. Trunin - MD, PhD.

Moscow

Competing Interests:

none

G. L. Kobyakov

Burdenko Neurosurgery Center
Russian Federation

Кобяков Григорий Львович - д.м.н.

Москва

Competing Interests:

none

Y. G. Sidneva

Burdenko Neurosurgery Center
Russian Federation

Yuliya G. Sidneva - PhD.

Moscow

Competing Interests:

none

References

1. Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33:6–26. doi: https://doi.org/10.1007/s12022-022-09703-7

2. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas; European Society of Endocrinology. Eur J Endocrinol. 2018;178(1): G1-G24. doi: https://doi.org/10.1530/EJE-17-0796

3. Burman P, Casar-Borota O, Gustavo Perez-Rivas L, Dekkers OM. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. The J Clin Endocrinol Metab. 2023;108(7):1585-1601. doi: https://doi.org/10.1210/clinem/dgad098

4. De Sousa SMC, McCormack AI. Aggressive Pituitary Tumors and Pituitary Carcinomas. Pituitary Disease and Neuroendocrinology Editor: Levy M, Korbonits M. January 5, 2022. www.endotext.org

5. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma. Cancer. 1997;79(4):804-812. doi: https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3

6. Yoo F, Kuan EC, Heaney AP, et al. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary. 2018;21:290–301. doi: https://doi.org/10.1007/s11102-018-0872-8

7. Kadashev BA, Astaf’eva LI, Shishkina LV, Rotin DL. Covremennyj vzglyad na problemu karcinomy gipofiza // Vestnik RONC im. N. N. Blohina RAMN. 2010;21(4):52-58 (InRuss.)

8. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022;187(4):593-605. doi: https://doi.org/10.1530/EJE-22-0440

9. Robertson IJ, Gregory TA, Waguespack SG, Penas-Prado M, Majd NK. Recent Therapeutic Advances in Pituitary Carcinoma. J Immunother Precis Oncol. (2023)6(2):74-83. doi: https://doi.org/10.36401/JIPO-22-25OxfordAcademic

Supplementary files

	1. Figure 1. MRI of the brain of patient S., 35 years old, shows tumors in the right temporal region and the posterior surface of the petrous temporal bone.
	Subject
	Type	Research Instrument
	View (244KB)	Indexing metadata ▾

	2. Figure 2. The PET/CT series reveals foci of pathological accumulation of 18F-FDG: in the greater wing of the sphenoid bone on the right with max SUV 4.85, according to CT - a soft tissue formation destroying the sphenoid bone and adjacent areas of the clivus and petrous temporal bone with the formation of an extraosseous component spreading intracranially and distally along the internal carotid artery to the level of C1, measuring about 2.8 x 1.5 cm (indicated by the arrow).
	Subject
	Type	Research Instrument
	View (270KB)	Indexing metadata ▾

	3. Figure 3. MRI (January 2016) - no data on tumor recurrence were found.
	Subject
	Type	Research Instrument
	View (216KB)	Indexing metadata ▾

	4. Figure 4. MRI (2020–2023) - no continued tumor growth was noted.
	Subject
	Type	Research Instrument
	View (462KB)	Indexing metadata ▾

Review

For citations:

Astafyeva L.I., Kalinin P.L., Trunin Y.Y., Kobyakov G.L., Sidneva Y.G. Efficacy of standard methods in the treatment of prolactin-secreting pituitary carcinoma. Problems of Endocrinology. 2024;70(5):40-45. (In Russ.) https://doi.org/10.14341/probl13401

Views: 579

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)